Answers are grounded in this paper and cite their sources.
OBJECTIVE: To assess the effectiveness of single-inhaler fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) in symptomatic chronic obstructive pulmonary disease (COPD) under real-world settings in China. METHODS: ), and proportion of CAT responders at Week 12. RESULTS: showed a clinically meaningful improvement from baseline with a mean of 0.13 L (95% CI = 0.10 ∼ 0.16). During the treatment, 10 (2.2%) participants reported FF/UMEC/VI-related adverse events. CONCLUSION: In real-world clinical practice in China, FF/UMEC/VI effectively improved symptoms and lung function in patients with symptomatic COPD and was well-tolerated.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: